About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ONTX
- Previous Close: $2.81
- 50 Day Moving Average: $2.70
- 200 Day Moving Average: $2.81
- 52-Week Range: $2.11 - $8.17
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.85
- P/E Growth: 0.00
- Market Cap: $18.99M
- Outstanding Shares: 6,759,000
- Beta: 0.07
- Net Margins: -73.67%
- Return on Equity: -148.52%
- Return on Assets: -50.49%
Companies Related to Onconova Therapeutics:
- Current Ratio: 3.10%
- Quick Ratio: 3.10%
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?
2 brokers have issued 1 year target prices for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Onconova Therapeutics' stock price to reach $20.50 in the next year.
When will Onconova Therapeutics announce their earnings?
Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
What are analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (4/1/2016)
HC Wainwright analysts commented, "Enrollment extends across the pond. Yesterday, Onconova announced that the Phase 3 INSPIRE trial of rigosertib in high-risk myelodysplastic syndromes (MDS) had enrolled its first patient in the EU. We view the news as a positive sign that Onconova remains fully committed to the study, despite the fact that Baxalta (BXLT; not rated) intends to pull out of the program in August. While Baxalta continues to offset trial costs for now, we expect that Onconova will need to re-partner the program or seek another means to fully fund the 225-patient trial, which we estimate could cost $23M to complete. We maintain our conviction that rigosertib has a place in the MDS treatment paradigm, and we see INSPIRE as the main value driver for the company. Additionally, rigosertib has shown compelling evidence of synergy with azacitidine, the current standard-of-care hypomethylating agent (HMA) in a front-line setting, and we expect to hear more about the company’s development plans for the combination later this year." (3/22/2016)
Who owns Onconova Therapeutics stock?
Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Boxer Capital LLC (4.68%) and Renaissance Technologies LLC (1.82%).
Who sold Onconova Therapeutics stock? Who is selling Onconova Therapeutics stock?
Onconova Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC.
Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?
Onconova Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy Onconova Therapeutics stock?
Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Onconova Therapeutics stock cost?
One share of Onconova Therapeutics stock can currently be purchased for approximately $2.81.